Vicky B. Gregg
Known title: DirectorCIK: 0001510304
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Acadia Healthcare Sets Q3 2026 Earnings Date. Acadia Healthcare announced the date for its third-quarter 2026 earnings release. This update provides a timeline for the next major financial report from the company. The stock is currently trading within its 52-week range of $11.43 to $35.83, with an average analyst target price of $33.79.
Transaction History
| DGX | ▲ Buy | Grant | 72 | $15K | 7/22/2026 | View on chart |
| DGX | ▲ Buy | Grant | 1,142 | $0 | 5/20/2026 | View on chart |
| ACHC | ▲ Buy | Grant | 6,331 | $0 | 5/6/2026 | View on chart |
| DGX | ▲ Buy | Grant | 68 | $13K | 4/20/2026 | View on chart |
| DGX | ▼ Sell | Other | 67 | $12K | 1/28/2026 | View on chart |
| DGX | ▼ Sell | Open Market | 1,250 | $240K | 11/25/2025 | View on chart |
| DGX | ▲ Buy | Grant | 70 | $13K | 10/21/2025 | View on chart |
| DGX | ▼ Sell | Other | 79 | $13K | 7/21/2025 | View on chart |
| ACHC | ▲ Buy | Grant | 7,032 | $0 | 5/29/2025 | View on chart |
| DGX | ▲ Buy | Grant | 1,203 | $0 | 5/15/2025 | View on chart |
| DGX | ▲ Buy | Grant | 68 | $11K | 4/21/2025 | View on chart |
| DGX | ▼ Sell | Open Market | 1,250 | $206K | 2/5/2025 | View on chart |
| DGX | ▼ Sell | Other | 72 | $11K | 1/29/2025 | View on chart |
| DGX | ▼ Sell | Other | 76 | $11K | 10/21/2024 | View on chart |
| DGX | ▼ Sell | Other | 77 | $11K | 7/22/2024 | View on chart |
| ACHC | ▲ Buy | Grant | 2,414 | $0 | 5/23/2024 | View on chart |
| DGX | ▲ Buy | Grant | 1,482 | $0 | 5/16/2024 | View on chart |
| DGX | ▲ Buy | Grant | 81 | $10K | 4/22/2024 | View on chart |
| ACHC | ▼ Sell | Open Market | 2,500 | $214K | 3/4/2024 | View on chart |
| DGX | ▼ Sell | Open Market | 2,500 | $317K | 2/23/2024 | View on chart |
| DGX | ▲ Buy | Grant | 88 | $11K | 1/31/2024 | View on chart |
| DGX | ▲ Buy | Grant | 92 | $11K | 10/23/2023 | View on chart |
| DGX | ▲ Buy | Grant | 78 | $11K | 7/25/2023 | View on chart |
| ACHC | ▲ Buy | Grant | 2,229 | $0 | 5/18/2023 | View on chart |
| DGX | ▲ Buy | Grant | 1,369 | $0 | 5/17/2023 | View on chart |
| DGX | ▼ Sell | Other | 72 | $10K | 4/24/2023 | View on chart |
| DGX | ▼ Sell | Other | 64 | $9K | 2/1/2023 | View on chart |
| DGX | ▼ Sell | Other | 74 | $9K | 10/19/2022 | View on chart |
| DGX | ▼ Sell | Other | 70 | $9K | 7/20/2022 | View on chart |
| ACHC | ▲ Buy | Grant | 2,303 | $0 | 5/19/2022 | View on chart |
| DGX | ▲ Buy | Grant | 1,292 | $0 | 5/18/2022 | View on chart |
| DGX | ▼ Sell | Other | 61 | $8K | 4/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus
Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus. Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.